

Our Mission:

- ❖ To raise awareness of the wide-spread incidence of Prostate Cancer and the need for early and annual screening exams,
- ❖ To provide information and support to men newly diagnosed with Prostate Cancer, and
- ❖ To foster research into better diagnostic tools and treatment options for Prostate Cancer.

Clinical Research – **RISK REDUCTION**

Dattoli Cancer Center joined a nation-wide clinical research program to test the safety and effectiveness of an investigational use of a FDA-approved drug in reducing the risk of developing prostate cancer.

Participants must be 50 to 75 years old and may suffer symptoms such as difficulty urinating and a frequent urge to urinate. They must have had only one negative prostate biopsy within the last 6 months. Volunteers meeting these and other criteria will be asked to undergo a screening visit to determine eligibility. Participants will be asked to complete approximately 10 additional scheduled clinic visits during the course of the 4-1/2 year study.

Profound Thoughts Needed!

Each year, the Foundation prints a daily calendar containing messages of hope and well being. Many have been submitted by prostate cancer patients themselves. We are currently working on the 2005 calendar, and we'd love to have your participation. Please mail, fax or email an original or favorite saying (please keep it short!) to Ginya Carnahan, and we will include you in the next addition.

You can contact Ginya at 1-800-915-1001; fax 941-330-2317; or by email at ginya.carnahan@dattoli.com.

SCANNING FOR OSTEOPOROSIS IN MEN

Hormonal therapy (androgen deprivation) is often prescribed for the treatment of prostate cancer and can be beneficial in slowing down the progression of the disease. Depending on the case, hormones may be used alone, or in combination with other treatment modalities such as IMRT and brachytherapy.

Osteoporosis involves a loss of bone or bone density and can increase the risk of fractures, particularly of the hip and compression fractures of the spine. Although the risk of osteoporosis is 2 to 4 times greater in women than in men, prolonged use of hormones for the treatment of prostate cancer can lead to significant bone loss.


Traditionally, DEXA scans have been widely used to evaluate bone density. DEXA scans provide 2-dimensional images of the density of cortical bone, the hard substance located on the outer part of the bone. However, technological advances have led to the QCT or "Quantitative Computed Tomography," bringing a more advanced method of diagnosing bone loss. Unlike the DEXA scan, QCT employs a 3-dimensional scanning method, and is able to measure the density and mass of trabecular bone, the spongy substance on the inside core of the bone, giving a far more accurate assessment of the condition. With a more precise diagnosis, individuals at risk for osteoporosis can begin preventative treatment earlier and prevent further bone loss.

We are now incorporating on site QCT scanning in our new patient evaluation for those men likely to need hormonal management or are on hormonal management at the time of consult. We are also using this evaluation for any of our patients who have had prior hormone management when we see them for their annual follow-ups.

*Submitted by Richard A. Sorace, MD, PhD
Dattoli Cancer Center Medical Director*



DATTOLI HONORED BY HOSPITAL



When over 1800 employees of Sarasota Memorial Hospital were asked "Do your physicians treat you with courtesy and respect?" they identified Dr. Michael Dattoli as one of the top 50 physicians who serve as role models for other members of the medical staff. Dr. Dattoli was recently honored by the hospital for his willingness and capability "to work with and relate to other staff members, members of other health disciplines, administration, employees, visitors and the community in general, in a cooperative, professional manner that is essential for maintaining a hospital environment appropriate to quality patient care." This, in addition to being honored as "Physician of the Quarter" in the 4th quarter of 2003 and the 1st quarter of 2004. We congratulate Dr. Dattoli!

AS SEEN IN PRINT

The May 2004 issue of "Renal & Urology News" featured an article by Dr. Dattoli, titled "Incurable PCa? Consider Brachytherapy." This journal, subtitled the World Review for Urologists & Nephrologists, is read by thousands of specialists in this country and others.

Dr. Dattoli states that "despite entering the mainstream (over a decade ago), patients diagnosed with intermediate and locally advanced high-risk prostate cancer are often discouraged from undergoing brachytherapy." In sharp contrast to this, Dr. Dattoli believes that brachytherapy is an appropriate and effective treatment for these men – and he has the data to substantiate this belief.

He cites a recent report in the journal "Cancer" that demonstrates a combination protocol of brachytherapy using palladium 103 and 3-D conformal EBRT produces outcomes superior to radical prostatectomy, with fewer side effects.

Dr. Dattoli's studies reveal 79% of these patients remaining cancer-free after 10 years, without the need for subsequent hormonal therapy or chemotherapy.

(Copies of this journal article are available from the Dattoli Cancer Foundation. Write or call for your copy – 1(800)915-1001). Dr. Dattoli is currently updating his data to 12-13 years, in cooperation with the University of Washington, Seattle.

*Gifts to the Dattoli Cancer Foundation are tax-deductible to the extent of the law
A 501 (c)(3) charitable organization, registered with the State of Florida.*

*Visit The Dattoli Cancer Foundation Website at
www.prostatetreatment.org*